Quick Answer
Vivos Therapeutics, Inc. reported Net Income of -$11.14 million for fiscal year 2024.
Vivos Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$11.14M | +18.0% |
| 2023 | -$13.58M | +43.0% |
| 2022 | -$23.84M | -17.5% |
| 2021 | -$20.29M | -68.3% |
| 2020 | -$12.06M | -12.1% |
| 2019 | -$10.75M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.40M | -106.4% | -7.7% |
| June 30, 2025 | -$5.01M | -159.7% | -29.7% |
| March 31, 2025 | -$3.86M | -2.7% | -47.7% |
| September 30, 2024 | -$2.62M | -25.0% | -35.5% |
| June 30, 2024 | -$1.93M | +65.1% | +48.7% |
| March 31, 2024 | -$3.76M | -121.0% | -79.8% |
| September 30, 2023 | -$2.09M | +61.5% | +62.1% |
| June 30, 2023 | -$5.53M | +20.9% | -224.6% |
- Vivos Therapeutics, Inc. showed an increase of +18.0% in Net Income compared to the prior fiscal year.
- Over the 2019–2024 period, Vivos Therapeutics, Inc.’s net income has declined by 3.5% (from -$10.75 million to -$11.14 million).
- The most recent figure is from Vivos Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: